Meetup

AlleyCorp Launches $1M Pitch Competition to Elevate Underrepresented Founders

Retrieved on: 
Monday, March 18, 2024
Business, Professional Services, Small Business, Thought Leadership, Entrepreneur, Female, Meetup, Partnership, Synovial joint, MLT, Peerless, Ecosystem, Economic development, Tech, Cryptocurrency

AlleyCorp, a New York-based venture capital firm that incubates and invests in transformative companies, today announced its inaugural pitch competition, Peerless, to support and elevate exceptional early-stage founders.

Key Points: 
  • AlleyCorp, a New York-based venture capital firm that incubates and invests in transformative companies, today announced its inaugural pitch competition, Peerless, to support and elevate exceptional early-stage founders.
  • In partnership with Management Leadership for Tomorrow (MLT), a national nonprofit focused on equipping and emboldening high-achieving individuals from underrepresented communities—Black, Latine, and Native American—the competition will aim to support early-stage founders from backgrounds that have been historically underfunded.
  • With less than 2% of venture capital dollars going toward female founders in 2023, in keeping with the shared commitment of AlleyCorp and MLT to diversify the startup ecosystem, Peerless will also be actively seeking submissions from female founders.
  • “Underrepresented founders are underfunded founders,” said Desiree Almodovar, Director at AlleyCorp, who is spearheading the competition.

Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials

Retrieved on: 
Thursday, March 14, 2024
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Automation, Friction, Software as a service, Meetup, Disease, FICS, General partnership, Organizational founder, Patient, BeiGene, Cancer, Hope, Investment, FDA, Food, Pharmaceutical industry

Pi Health , an oncology-focused health technology and clinical research company committed to transforming global access to innovative medicines and clinical trials, today announced over $30M in Series A funding.

Key Points: 
  • Pi Health , an oncology-focused health technology and clinical research company committed to transforming global access to innovative medicines and clinical trials, today announced over $30M in Series A funding.
  • Pi Health, which incubated as a subsidiary of BeiGene, Ltd. (NASDAQ: BGNE) three years ago, completed its fundraise to launch as an independent company.
  • None has taken the bold, comprehensive and global approach that Pi Health has,” said Brenton Fargnoli, M.D., General Partner at AlleyCorp.
  • “Pi Health has the potential to bring life-saving drugs and treatments to market faster and more efficiently, ultimately saving countless lives in the process.

Conduce Health Secures $3 Million in Seed Funding to Power Multi-Specialty Value-Based Care Marketplace

Retrieved on: 
Wednesday, March 20, 2024
Meetup, Entrepreneurship, Data science, Health, Patient, PCP, MD, Senior, Primary care, Medicare, Nursing

NEW YORK, March 20, 2024 /PRNewswire-PRWeb/ -- Conduce Health (Conduce), a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations and specialists, announced today the closing of a $3 million seed round led by Connecticut Innovations with participation from AlleyCorp, CityLight, and other strategic investors. As value-based models continue to focus on the next frontier of specialty care, Conduce's marketplace provides a turnkey solution for primary care organizations managing specialty risk, local specialists, and single-specialty companies seeking to take on higher patient volumes with risk-based economics.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire-PRWeb/ -- Conduce Health (Conduce), a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations and specialists, announced today the closing of a $3 million seed round led by Connecticut Innovations with participation from AlleyCorp, CityLight, and other strategic investors.
  • Specialty care and the subsequent management of complex chronic diseases comprise over 60% of medical expenditure in the United States.
  • Conduce's marketplace is now live and supporting patient care in South Carolina and Georgia with ambitions to expand throughout the Southeast.
  • In addition to existing primary care and specialist partnerships, Conduce is looking to rapidly grow its marketplace.

Chamber Secures $8 Million in Funding to Empower Cardiologists to Transition into Value-Based Care

Retrieved on: 
Wednesday, March 6, 2024
Chamber, Cardiovascular disease, Cardiology, Ageing, Entrepreneurship, Frustration, VBC, Head, Health, Patient, City Lights, BCBS, Mortality, Mid-Atlantic (United States), Meetup, Partnership, Health insurance

WASHINGTON, March 6, 2024 /PRNewswire/ -- Chamber Cardio (Chamber), a technology-enabled cardiology solution, announced today an $8 million seed round led by General Catalyst with support from existing investor AlleyCorp and participation from Company Ventures, American Family Ventures, and City Light. In an industry where the transition to value-based care remains limited among cardiologists, Chamber emerges as a dedicated partner, uniquely positioned to support and collaborate with cardiology practices.

Key Points: 
  • In an industry where the transition to value-based care remains limited among cardiologists, Chamber emerges as a dedicated partner, uniquely positioned to support and collaborate with cardiology practices.
  • Cardiovascular disease drives over $400 billion in annual healthcare expenditures, and Chamber aims to tackle this issue head-on by making the transition to value-based care more accessible.
  • The funding will be utilized to further develop Chamber's technology, expand the cardiology network nationally, and grow the team.
  • Chamber addresses this by equipping cardiologists with real-time insights, evidence-based guidelines, care teams, and contracting support to streamline workflows, enabling them to focus on patient care.

VALISURE ANNOUNCES NEW VENTURE PARTNERS AND EXPANSION OF LEADERSHIP TEAM

Retrieved on: 
Wednesday, February 28, 2024
Engineering, CVS Health, Teva Pharmaceuticals, MinuteClinic, Research, Chemistry, Walgreens, Investment, University of Cambridge, Health, Growth, Overalls, Harvard University, Government, Mathematics, Ion semiconductor sequencing, Safety, Health care, University, Yale University, CVS, Thermo Fisher Scientific, Economics, Robotics, Medicaid, Social impact, Biology, Meetup, Expansion, DNA, Public, Management

NEW HAVEN, Conn., Feb. 28, 2024 /PRNewswire/ -- Valisure, a healthcare industry pioneer for independent quality assurance in pharmaceutical drugs, has recently received substantial investments from leading healthcare venture capital firms to accelerate Valisure's rapid growth and impact. Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.

Key Points: 
  • Concurrently, the company is pleased to announce key leadership developments, including appointing a highly experienced healthcare leader as CEO and additional expansion of its executive team.
  • Valisure has gained global recognition for its commitment to ensuring the safety and quality of medications through its highly impactful, independent testing.
  • "I look forward to collaborating with the talented team and enabling Valisure to expand its work with the industry to strategically address these issues."
  • Likewise, Wolfgang Hinz, Ph.D., has assumed a pivotal leadership position as the Chief Scientific Officer of Valisure.

Vicarius Raises $30M Series B to Fuel AI Innovations in Vulnerability Remediation

Retrieved on: 
Wednesday, January 17, 2024
Software, Technology, Artificial Intelligence, Security, Research, Pixel, PLG, Meetup, AI, PepsiCo, VM, Risk, JVP, Videocassette recorder, Investment, HPE, Equinix, CVE, Organization, Sonae, Automation, Hewlett Packard Enterprise, LLM, Growth

Vicarius , developers of vRx, the industry’s first fully autonomous end-to-end vulnerability remediation platform, today announced a $30 million Series B led by cybersecurity investment firm Bright Pixel (formerly Sonae IM).

Key Points: 
  • Vicarius , developers of vRx, the industry’s first fully autonomous end-to-end vulnerability remediation platform, today announced a $30 million Series B led by cybersecurity investment firm Bright Pixel (formerly Sonae IM).
  • Vicarius is disrupting the market with fully automated and autonomous vulnerability remediation solutions that proactively reduce cyber risk for businesses.
  • Leveraging in-house AI technology, Vicarius automates much of the discovery, prioritization, and remediation workload plaguing security and IT teams.
  • “Vicarius is best positioned to take on the much-needed task of transforming the vulnerability management market from assessment to remediation.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

Inductive Bio Emerges from Stealth, Unveiling an ML Platform to Accelerate Compound Optimization in Drug Discovery

Retrieved on: 
Wednesday, December 13, 2023
Meetup, Character, Lux Capital, ADMET, Therapy, QSAR, Data, Patient, Algorithm, Atlas Venture, Machine learning, Absorption, Flatiron, Drug discovery, Hand, Roche, Pain, ADME, Atlas, Metabolism, SVP, Genentech, Pharmaceutical industry, Induction, Venture, Toxicity

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Inductive Bio, a technology company developing a machine learning (ML) platform designed to dramatically accelerate the compound optimization process, emerged from stealth today with $4.3M in funding.
  • Their seed round was co-led by Andreessen Horowitz (a16z) Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others.
  • Inductive Bio was co-founded by Josh Haimson and Ben Birnbaum who had previously built out the ML organization at Flatiron Health, which was acquired by Roche in 2018.
  • Denali has integrated custom ADME models from Inductive into their small molecule drug design platform to support rapid, data-driven decision making.

EnCharge AI Closes Additional $22.6M from VentureTech Alliance, RTX Ventures and ACVC Partners to Unlock AI Compute

Retrieved on: 
Tuesday, December 5, 2023
Meetup, Silicon, Artificial intelligence, Growth, AI, Workload, Architecture, Medical device

SANTA CLARA, Calif., Dec. 5, 2023 /PRNewswire/ -- EnCharge AI, the company developing advanced AI chips and full stack solutions, today announced it has closed a second institutional round of funding from strategic partners including VentureTech Alliance, RTX Ventures, and ACVC Partners with participation from existing investors such as Anzu Partners, AlleyCorp, Scout VC, Silicon Catalyst Angels and S5V. The funding round underscores the demand for new AI chips capable of running AI system workloads at a far lower cost and with greater efficiency than previously thought possible.

Key Points: 
  • "The computational needs of AI push the limits of today's enterprises, resulting in expensive operations, environmental issues, and inadequate performance.
  • "None of the AI chip architectures on the market today are fully equipped for the future of AI.
  • Encharge AI is solving critical issues around computing power, accessibility and costs that are both limiting AI today and inadequate for handling AI of tomorrow.
  • To learn more about EnCharge AI and how it can unlock AI compute, please visit here .